Pulmonary arterial hypertension (PAH) results from severe remodeling of the distal lung vessels, and can develop from unknown (idiopathic, IPAH) causes as well as diseases such as systemic sclerosis (SSc), a disorder characterized by endothelial and fibroblast dysregulation, and altered immunity. Right ventricular (RV) failure, the major cause of death with PAH, is particularly prominent in SSc-associated PAH (SSc-PAH) while important in all PAH. Despite modern therapy, SSc-PAH has a median survival of only 3 years, far worse than IPAH. We recently identified novel hemodynamic and non-invasive image-based risk factors predictive of survival and, in new preliminary data, reveal abnormal RV myocardial contractility in SSc-PAH. We propose that worse survival in SSc-PAH versus IPAH results from intrinsic RV dysfunction independent of pulmonary arterial (PA) loading, which is due in part to sarcomeric dysfunction and micro-vascular disease. We will fill major knowledge gaps regarding RV-PA disease in SSc-PAH and IPAH, and test new invasive and non- invasive clinical measures of RV function in PAH to reveal novel mechanisms and markers of disease evolution and risk. The three Specific Aims will 1) derive optimal non-invasive measures of RV performance based on cardiac magnetic resonance imaging to predict survival in both IPAH and SSc-PAH;2) determine RV function and PA interaction by invasive pressure-volume and right heart catheterization, using rate pacing and leg-exercise to assess reserve RV function;and 3) obtain RV biopsies to test the role of primary sarcomere dysfunction to reduced RV contractility in PAH (either form), identify cytokine activation pathways linked to transforming growth factor-beta cascades and angiogenesis modulators, and assess the potential for associated serum biomarkers to reflect RV disease. This will provide critically needed insights into RV function and novel biomarkers (functional and signaling) to assess RV dysfunction, which can be used clinically. We will also provide the first myofilament analysis and assessment of molecular pathways in human myocardial tissue in PAH, coupling this to intact organ physiology, and yielding critical new insights that can pave the way to future therapies aimed at improving RV function in PAH.

Public Health Relevance

This application will: 1) establish standard clinical imaging and hemodynamic biomarkers of RV function in PAH;2) identify the cause of RV dysfunction and role in SSc-PAH survival;and 3) unravel pathogenic mechanisms underlying altered myocardial contractile function in PAH that can serve as future therapeutic targets for RV dysfunction in PAH.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL114910-01
Application #
8353603
Study Section
Special Emphasis Panel (ZHL1-CSR-H (M1))
Program Officer
Moore, Timothy M
Project Start
2012-08-15
Project End
2017-05-31
Budget Start
2012-08-15
Budget End
2013-05-31
Support Year
1
Fiscal Year
2012
Total Cost
$703,702
Indirect Cost
$268,896
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Houston, Brian A; Kalathiya, Rohan J; Hsu, Steven et al. (2016) Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. J Heart Lung Transplant 35:868-76
Hsu, Steven; Houston, Brian A; Tampakakis, Emmanouil et al. (2016) Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. Circulation 133:2413-22
Hsu, Steven; Kass, David A (2016) Can Nitrite AMPk Up Sirt-ainty to Treat Heart Failure With Preserved Ejection Fraction? Circulation 133:692-4
Yang, Jun; Nies, Melanie K; Fu, Zongming et al. (2016) Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 194:1264-1272
Shah, Sanjiv J; Kitzman, Dalane W; Borlaug, Barry A et al. (2016) Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 134:73-90
Teerlink, John R; Malik, Fady I; Kass, David A (2015) Letter by Teerlink et al Regarding Article, ""Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity"". Circ Heart Fail 8:1141
Damico, Rachel; Kolb, Todd M; Valera, Lidenys et al. (2015) Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 191:208-18
Ryan, John J; Tedford, Ryan J (2015) Diagnosing and treating the failing right heart. Curr Opin Cardiol 30:292-300
Kolb, Todd M; Peabody, Jacelyn; Baddoura, Philip et al. (2015) Right Ventricular Angiogenesis is an Early Adaptive Response to Chronic Hypoxia-Induced Pulmonary Hypertension. Microcirculation 22:724-36
Kirk, Jonathan A; Kass, David A (2015) Cellular and Molecular Aspects of Dyssynchrony and Resynchronization. Card Electrophysiol Clin 7:585-97

Showing the most recent 10 out of 21 publications